Publications by authors named "Rosalba Carullo"
Overcoming treatment-resistant depression with machine-learning based tools: a study protocol combining EEG and clinical data to personalize glutamatergic and brain stimulation interventions (SelecTool Project).
Front Psychiatry
July 2024
Article Synopsis
- Treatment-Resistant Depression (TRD) is a significant health issue that's hard to tackle due to its complex nature and varied symptoms, prompting the need for better treatment strategies.
- The SelecTool Project is introduced as a computational tool that combines clinical data, EEG, and blood biomarkers using machine learning to personalize TRD treatments, specifically focusing on esketamine nasal spray and accelerated repetitive Transcranial Magnetic Stimulation.
- The project involves two main phases: first, a study with 100 TRD subjects to evaluate the effectiveness of treatments, and then training the tool to assist in managing an additional 20 subjects, ultimately aiming to improve TRD treatment outcomes through advanced data analysis.
The article presents a systematic literature review on the use and the psychiatric implications of over-the-counter drugs (OTC), prescription-only-medications (POM), and new psychoactive substances (NPS) within custodial settings. The searches wer carried out on 2 November 2022 on PubMed, Scopus, and Web of Science in line with PRISMA guidelines. A total of 538 records were identified, of which 37 met the inclusion criteria.
View Article and Find Full Text PDFIntroduction: Intravenous ketamine (KET-IV) and intranasal esketamine (ESK-NS) are effective in the acute treatment of Treatment-Resistant Depression (TRD). Studies comparing KET-IV and ESK-NS concerning their action, safety, and tolerability are currently lacking.
Materials And Methods: We combined patients' data from two unipolar TRD cohorts that received KET-IV (n = 171) at the Canadian Rapid Treatment Center of Excellence in Toronto, Canada, or ESK-NS (n = 140) at several TRD clinics in Italy.
Treatment-resistant depression (TRD) represents a severe clinical condition with high social and economic costs. Esketamine Nasal Spray (ESK-NS) has recently been approved for TRD by EMA and FDA, but data about predictors of response are still lacking. Thus, a tool that can predict the individual patients' probability of response to ESK-NS is needed.
View Article and Find Full Text PDFIntroduction: Treatment-resistant depression (TRD) is a serious and debilitating psychiatric disorder that frequently affects older patients. Esketamine nasal spray (ESK-NS) has recently been approved as a treatment for TRD, with multiple studies establishing its efficacy and tolerability. However, the real-world effectiveness, tolerability, and safety of this treatment in older adults is still unclear.
View Article and Find Full Text PDF